Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Icu Medical (ICUI) Research & Development (2016 - 2025)

Historic Research & Development for Icu Medical (ICUI) over the last 17 years, with Q3 2025 value amounting to $21.3 million.

  • Icu Medical's Research & Development rose 106.05% to $21.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.8 million, marking a year-over-year increase of 10.49%. This contributed to the annual value of $88.6 million for FY2024, which is 383.27% up from last year.
  • According to the latest figures from Q3 2025, Icu Medical's Research & Development is $21.3 million, which was up 106.05% from $21.9 million recorded in Q2 2025.
  • Over the past 5 years, Icu Medical's Research & Development peaked at $23.9 million during Q1 2022, and registered a low of $10.7 million during Q1 2021.
  • For the 5-year period, Icu Medical's Research & Development averaged around $20.0 million, with its median value being $21.9 million (2025).
  • In the last 5 years, Icu Medical's Research & Development skyrocketed by 12290.6% in 2022 and then crashed by 1721.75% in 2023.
  • Over the past 5 years, Icu Medical's Research & Development (Quarter) stood at $13.2 million in 2021, then soared by 78.08% to $23.4 million in 2022, then dropped by 4.41% to $22.4 million in 2023, then dropped by 0.25% to $22.4 million in 2024, then dropped by 4.94% to $21.3 million in 2025.
  • Its Research & Development stands at $21.3 million for Q3 2025, versus $21.9 million for Q2 2025 and $23.3 million for Q1 2025.